Situation · 2026-06-12

ABVX.PA — Profile and price weak

Discounted for a Reason: Abivax’s Losses Eclipse Growth

Updated 2026-06-04 · Ref: Healthcare

Key metrics — 2026-06-04

Peer score

Quality pct

Valuation pct

52w drawdown

-31.4%

21d vs sector

-40.0%

Peer group

Healthcare

Situation summary

Abivax is cheap, but the losses are overwhelming. The market prices survival, not growth, with an operating margin of -4183.7%. This is a biotech bet on clinical milestones. Growth means little when the red ink runs this deep.

Published by AssetNext · 2026-06-06

All companies with this signal today

View full list: Profile and price weak →

Related pages for ABVX.PA

Full peer analysis for ABIVAX Société Anonyme →Similar companies to ABVX.PA ABVX.PA peers All ABVX.PA comparisons STOXX 600 context

Signal history — last 30 days

Date	Signal	Peer score	Drawdown	21d vs sector
2026-06-04	Profile and price weak	38	-31.4%	-40.0%
2026-05-29	Profile and price weak	38	-7.4%	-13.4%

See ABVX.PA's full peer analysis

Break down ABVX.PA's structural position across all peer dimensions with the interactive app.

Open ABVX.PA in AssetNext →